Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736839 · ClinicalTrials.gov registry record
Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution
A clinical trial, sponsored by National Jewish Health.
- Completed
- Registry status
- 23
- Enrollment target
NCT01736839 is a clinical trial that has completed, run by National Jewish Health. The registered enrollment target is 23 participants.
The verdict
NCT01736839 has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
In cystic fibrosis, there is a critical need for better predictors of treatment response. The investigators have identified a panel of white blood cell biomarkers which can be directly measured as a blood test in subjects with cystic fibrosis. These biomarkers predict reduction of airway inflammation and infection more accurately than lung function testing, in patients receiving intravenous antibiotic therapy. In the current study, we hypothesize that this panel of gene biomarkers which can be readily measured from peripheral blood will sensitively predict changes in inflammation when patients receive inhaled antibiotic therapy, specifically Cayston (or inhaled aztreonam lysine). Patients enrolled in the study will have blood drawn before and after a month of inhaled Cayston, in order to test whether genes predict response to Cayston therapy more robustly than do standard measures such as lung function tests.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-11 |
| Est. Completion | 2017-07-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01736839
The ClinicalTrials.gov registry entry for NCT01736839 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01736839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01736839 about?
NCT01736839 is a clinical study titled "Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution". In cystic fibrosis, there is a critical need for better predictors of treatment response. The investigators have identified a panel of white blood cell biomarkers which can be directly measured as a blood test in subjects with cystic fibrosis. These biomarkers predict reduction of airway inflammatio...
What is the current status of trial NCT01736839?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2012-11. Estimated completion is 2017-07-27.
Who is sponsoring clinical trial NCT01736839?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.